Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can growth hormone make short boys stronger?

NCT ID NCT04020913

Disease control Sponsor: Nemours Children's Clinic Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study looked at whether growth hormone therapy can improve muscle strength, power, and body composition in short prepubertal boys, both those with growth hormone deficiency and those with idiopathic short stature. Thirty short boys received growth hormone injections for 12 months, and their results were compared to 15 normally growing boys not on the hormone. The goal was to see if growth hormone does more than just increase height.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Somatropin (recombinant growth hormone, Norditropin)
What this could lead to
If successful, this could show that growth hormone therapy improves not just height but also muscle strength and function in short boys.
What could go wrong
This is a small, completed study with only 45 participants, so results may not apply to all short boys. Growth hormone therapy also carries risks like joint pain and fluid retention.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

45 people

The number who actually took part.

Started

Jul 2019

Finished

Oct 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Prepubertal boys with short stature defined as a height ≤-2 SDS with either GH deficiency (i.e., peak GH responses to pharmacologic stimuli \<10ng/ml) or idiopathic short stature (i.e., normal GH, no identifiable pathology) will be studied. Normally Statured Boys: A group of 15 healthy, normally statured (between 10th- 90th %), age-matched boys not on somatropin, preferably siblings (although not exclusively) will be studied similarly.

Ages

6 to 11 years

Sex

Male participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Short Stature Group 1. 30 boys between 6-11 years of age 2. Prepubertal 3. Short stature (height ≤ -2SDS) due to either GH deficiency or idiopathic 4. Stable treatment of other pituitary hormone deficiencies 5. Naïve to GH therapy, or GH discontinued at least 6 months prior to study Normal Stature Group 1. 15 boys between 6-11 years of age 2. Prepubertal 3. Normal height (10th to 90th%) Exclusion Criteria: 1. Actively growing brain tumors 2. Chronic medical conditions that could affect study outcomes 3. Long-term steroid use 4. Intense regular physical training programs or organized team sports

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Growth hormone deficiency are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Dwarfism isolated congenital growth hormone deficiency isolated short stature pituitary dwarfism

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Growth hormone deficiency Idiopathic short stature

Contacts and locations

Locations

  • Nemours Children's Clinic

    Jacksonville, Florida, 32207, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.